-
-
-
-
-
-
-
Intellia short interest rises most among biotech stocks in latest period - Baird
-
-
-
-
-
-
-
CRISPR Therapeutics outlines 2026 milestones with $2 billion cash
-
-
-
-
-
-
-
CRISPR Therapeutics' (CRSP) Drug Shows Promising Lipid Lowering Results - Citizens
-
-
-
-
-
-
-
FDA Clears Way for Faster Personalized Gene Editing Treatments
-
-
-
-
-
-
-
JPMorgan Starts CRISPR Therapeutics (CRSP) at Overweight
-
-
-
-
-
-
-
Citizens JMP Reiterates Market Outperform Rating on CRISPR Therapeutics (CRSP)
-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) Reports Positive Additional Phase 1 Data for CTX310 Targeting ANGPTL3
-
433,981 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

